CYP3A4 and acute coronary syndrome: 6.58 × (CrCl/93)0.406   × (BW/81) −0.278   × 0.966 (if co-medication with P-pg inhibitor)   × 0.978 (if co-medication with strong CYP3A4 inhibitors)   × 0.863 (if co-medication with moderate CYP3A4 inhibitors)   × 0.939 (if co-medication with weak CYP3A4 inhibitors)   × 1.30 (if co-medication with CYP3A4 inducers)   × 1 (if venous thromboembolism treatment)   × 0.849 (if non-valvular atrial fibrillation)   × 1.14 (if acute coronary syndromes)   × 1.04 (if venous thromboembolism prevention, < 72 h)   × 1.29 (if venous thromboembolism prevention, ≥ 72 h)